TANFAC Industries has emerged as one of the standout wealth creators in the Indian specialty chemicals space. The stock has surged nearly 1,800% over the last five years, taking its market capitalization to around ₹6,200 crore. The company has also attracted several well-known investors, including Ashish Kacholia, Vanaja Sundar Iyer, Madhulika Agarwal, and Malabar Fund, reflecting growing institutional confidence in its long-term growth prospects.
Riding the Fluorochemical Demand Wave
TANFAC is well-positioned to capitalize on the structural demand growth in the fluorochemicals industry. The company’s strategic expansion plans, combined with healthy order visibility and strong execution, are expected to drive the next phase of earnings growth.
A major catalyst is the company’s upcoming R-32 refrigerant project, where approximately 65% of the planned production capacity has already been contracted, providing strong revenue visibility even before commissioning. Rising global demand for environmentally friendlier refrigerants is expected to support sustained demand for R-32 over the coming years.
Strong Balance Sheet Supporting Aggressive Expansion
To fund its growth ambitions, TANFAC recently raised around ₹350 crore from marquee investors. These funds, along with internal accruals, will finance a capital expenditure program of nearly ₹400 crore for the new R-32 plant.
The expansion does not stop there. The company has also announced:
- ₹150 crore investment towards a new Hydrofluoric Acid (HF) plant with a capacity of 17,160 MTPA
- ₹40 crore investment towards a new Sulphuric Acid Plant (SAP) with a capacity of 82,500 MTPA
Once all three projects become operational, TANFAC’s manufacturing capacity is expected to increase to nearly 1.8 times its current level, significantly enhancing its ability to serve growing domestic and export demand.
Earnings Growth Expected to Accelerate
According to the research report by Choice Securities, the company is entering a phase of strong operating leverage.
The brokerage estimates:
- Revenue CAGR of approximately 40% between FY26 and FY29E
- Profit After Tax (PAT) CAGR of approximately 52% during the same period
The growth is expected to be driven by capacity expansion, better product mix, and higher-margin specialty fluorochemical products.
Margin Expansion Could Drive Re-Rating
One of the key positives highlighted in the report is the expected improvement in operating margins.
The brokerage expects EBITDA margins to improve to nearly 23% by FY28, representing an expansion of around 500 basis points. This improvement is largely attributed to the significantly higher realizations from the R-32 business compared to conventional Hydrofluoric Acid products.
As higher-margin products contribute a larger share of revenue, profitability and cash flow generation are expected to strengthen meaningfully.
Attractive Valuation Despite Strong Rally
Despite its remarkable stock performance over the past five years, Choice Securities believes TANFAC still offers meaningful upside.
Using a Discounted Cash Flow (DCF) valuation methodology, the brokerage has assigned a target price of ₹3,750, implying an upside of roughly 44% from the report’s reference price.
The report also notes that:
- TANFAC trades at around 25x FY28E forward earnings
- Comparable specialty chemical peers trade at a median valuation of around 38x forward PE
- The implied PEG ratio of 0.67x suggests the stock remains reasonably valued relative to its expected earnings growth
This valuation discount, combined with strong earnings visibility, positions TANFAC as a potential re-rating candidate.
Key Risks to Watch
While the long-term outlook appears encouraging, investors should remain aware of the key risks:
- Dependence on imported raw materials
- Volatility in feedstock prices
- Cyclicality in Hydrofluoric Acid demand
- Environmental and operational safety risks
- Customer and product concentration
- Potential delays or non-allocation of production quotas
Conclusion
TANFAC appears to be entering a transformational phase supported by large capacity expansions, improving product mix, contracted revenue visibility, and strong industry tailwinds. With a healthy balance sheet, significant earnings growth potential, and relatively attractive valuations compared to peers, the company is increasingly being viewed as a compelling long-term specialty chemicals opportunity.
That said, investors should remember that brokerage target prices and earnings estimates are projections rather than guarantees. Investment decisions should be based on individual risk appetite, independent research, and continuous monitoring of the company’s execution and industry developments.
